[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360308-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360308-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-impact-of-statins-on-prognostic-outcomes-in-patients-with-non-metastatic-solid-cancers-a-systematic-review-and-meta-analysis","The impact of statins on prognostic outcomes in patients with non-metastatic solid cancers - a systematic review and meta-analysis","","Statins are widely used low-density lipoprotein-lowering drugs, and their pleiotropic effects may influence cancer progression. This systematic review and meta-analysis evaluates the association between statin use and prognostic outcomes in patients with non-metastatic solid cancers. Following PRISMA guidance, literature was searched across PubMed, the Cochrane Library, and Web of Science, with PICO framing and time-to-event meta-analyses. Outcomes included overall survival, disease-free survival, recurrence-free survival, and cancer-specific survival, alongside tumor microenvironment considerations, with bias assessed via the Newcastle-Ottawa Scale and evidence quality via modified GRADE.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-impact-of-statins-on-prognostic-outcomes-in-patients-with-non-metastatic-solid-cancers-a-systematic-review-and-meta-analysis/360308/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-impact-of-statins-on-prognostic-outcomes-in-patients-with-non-metastatic-solid-cancers-a-systematic-review-and-meta-analysis/360308.png","ImageObject",300,407,{"name":42,"@type":43},"Pentious","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main aim of the study?","Question",{"text":63,"@type":64},"To examine the association between statin use and prognostic outcomes in patients with non-metastatic solid cancers using a systematic review and meta-analysis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were eligible studies selected and analyzed?",{"text":68,"@type":64},"The review followed PRISMA guidelines, used a PICO-based search across PubMed, the Cochrane Library, and Web of Science, and performed meta-analyses of time-to-event outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"Which prognostic outcomes were evaluated?",{"text":72,"@type":64},"Overall survival, disease-free survival, recurrence-free survival, and cancer-specific survival were evaluated, and the study also considered the tumor microenvironment as an outcome.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360308,1790192701,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Ayhan et al. Discover Oncology (2026) 17:812 [https://doi.org/10.1007/s12672-026-04887-4](https://doi.org/10.1007/s12672-026-04887-4)  \nDiscover Oncology  \nREVIEW Open Access  \nThe impact of statins on prognostic outcomes in patients with non-metastatic solid cancers: a systematic review and meta-analysis  \nEmine Ceren Ayhan1*†, Sule Eraslan1†, Michael Tvilling Madsen2, Tobias Freyberg Justesen1, Josefine Freyberg Justesen3, Ismail Gögenur1,4 and Adile Orhan1  \n†Emine Ceren Ayhan and Sule Eraslan shared first authorship.  \n*Correspondence:  \nEmine Ceren Ayhan [eay@regionsjaelland.dk](eay@regionsjaelland.dk)[ ](eay@regionsjaelland.dk)1Department of Surgery, Center for Surgical Science, Zealand University Hospital, Køge Lykkebaekvej 1, Køge 4600, Denmark 2Department of Surgery, Midt og Vest Sjaellands Hospital, Slagelse, Denmark  \n3Department of Clinical Biochemistry, Zealand University Hospital, Køge, Denmark 4Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark  \nAbstract  \nBackground Statins are commonly prescribed low-density lipoprotein-lowering drugs that have been used in patients with cancer due to their pleiotropic effects. In this paper, the association between statin use and prognostic outcomes was examined inpatients with non-metastatic solid cancer.  \nMethods In accordance with the PRISMA guidelines, a systematic review of the literature was conducted, and meta-analyses of time-to-event outcomes were performed. The literature search was designed using the Participants, Intervention, Comparator, and Outcome (PICO) framework. The search was completed across three different databases: PubMed, The Cochrane Library, and Web of Science. Studies investigating the impact of statin use versus no statin use on oncological survival measures in patients with non-metastatic solid cancers were eligible for inclusion. The outcomes of interest were overall survival (OS), disease-free survival (DFS), recurrencefree survival (RFS), and cancer-specific survival (CSS) . Furthermore, the impact of statin use on the tumor microenvironment was an outcome of interest. The risk of bias was assessed using the Newcastle-Ottawa Scale and the quality of the cumulative evidence was evaluated using the modified GRADE approach.  \nFindings A total of 4,131 articles were title and abstract screened of which 106 articles were included in the systematic review and 90 articles in the meta-analysis. The total number of included patients in the meta-analysis was 472,004 Statin use in patients with non-metastatic solid cancer was significantly associated with improved OS (hazard ratio (HR) = 0 . 84, 95% confidence interval (CI): 0 .80–0. 88, I2: 89%), RFS (HR = 0 . 78, 95% CI: 0 .69–0. 88, I2: 84%), and CSS (HR = 0 . 86, 95% CI: 0 .81–0. 91, I2: 81%) . Statin use showed significantly improved OS in patients with gastrointestinal cancer (HR = 0 . 79, 95% CI: 0 .72–0. 87, I2: 88%), urological cancer (HR = 0 . 85, 95% CI: 0 .77–0. 94, I2: 86%), and gynecological cancer (HR = 0 . 84, 95% CI: 0 .74–0. 95, I2: 0%) . Conclusions. Statin therapy was associated with improved survival outcomes in patients with non-metastatic solid cancer, especially in gastrointestinal, urological and gynecological cancers.  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not inc","cbCaitt4Rm5KOTmg","https://ap.wps.com/l/cbCaitt4Rm5KOTmg","pdf",2754855,26,"English","# Abstract\n## Background\n## Methods\n## Findings\n## Conclusions\n# Introduction\n## Global cancer burden\n## Tumor microenvironment and drug repurposing\n## Statins and mechanistic rationale","[{\"question\":\"What is the main aim of the study?\",\"answer\":\"To examine the association between statin use and prognostic outcomes in patients with non-metastatic solid cancers using a systematic review and meta-analysis.\"},{\"question\":\"How were eligible studies selected and analyzed?\",\"answer\":\"The review followed PRISMA guidelines, used a PICO-based search across PubMed, the Cochrane Library, and Web of Science, and performed meta-analyses of time-to-event outcomes.\"},{\"question\":\"Which prognostic outcomes were evaluated?\",\"answer\":\"Overall survival, disease-free survival, recurrence-free survival, and cancer-specific survival were evaluated, and the study also considered the tumor microenvironment as an outcome.\"}]","The impact of statins on prognostic outcomes in patients with non-metastatic solid cancers - a systematic review and meta-analysis | PDF",1790139548,66,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c38394a0128a1ee0970e98e277441d2f.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bce1a565f68607fdf2ade4bbe3eb6e2d.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaaa543c59c6fcc45010394b699dd5d9.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34e415eeeef272648eabbe11c54962fb.webp",980,1306]